Engineered Salmonella typhimurium expressing E7 fusion protein, derived from human papillomavirus, inhibits tumor growth in cervical tumor-bearing mice

Biotechnology Letters

Volumn 36, Issue 2, 2014, Pages 349-356

  Yoon, Wonsuck ^a   Choi, Ji Hyeon ^a   Kim, Sinyeon ^a   Park, Yong Keun ^a  

^a Korea University   (South Korea)

Author keywords

Anti tumor effect; Cancer therapy; Cervical cancer; HPV 16 E7; Human papillomavirus; Salmonella typhimurium; Tumor retardation

Indexed keywords

BEARINGS (MACHINE PARTS); CELL DEATH; DISEASES; GLYCOPROTEINS; MAMMALS; ONCOGENIC VIRUSES; PROTEINS; SALMONELLA;

ANTITUMOR EFFECT; CANCER THERAPY; CERVICAL CANCERS; HPV 16 E7; HUMAN PAPILLOMAVIRUS; SALMONELLA TYPHIMURIUM;

TUMORS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MUS; SALMONELLA; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM; SALMONELLA TYPHIMURIUM;

BACTERIAL PROTEIN; BIOLOGICAL PRODUCT; HYBRID PROTEIN; INVASION PROTEIN B, SALMONELLA TYPHIMURIUM; MEMBRANE PROTEIN; PROTEIN E7;

ANIMAL; ARTICLE; DISEASE MODEL; FEMALE; GENETICS; METABOLIC ENGINEERING; METABOLISM; MOUSE; SALMONELLA TYPHIMURIUM; SURVIVAL; UTERINE CERVIX TUMOR;

ANIMALS; BACTERIAL PROTEINS; BIOLOGICAL PRODUCTS; DISEASE MODELS, ANIMAL; FEMALE; MEMBRANE PROTEINS; METABOLIC ENGINEERING; MICE; PAPILLOMAVIRUS E7 PROTEINS; RECOMBINANT FUSION PROTEINS; SALMONELLA TYPHIMURIUM; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 84892555297     PISSN: 01415492     EISSN: 15736776     Source Type: Journal    
DOI: 10.1007/s10529-013-1370-8     Document Type: Article

References (14)

1. Bolhassani A, Mohit E, Rafati S (2009) Different spectra of therapeutic vaccine development against HPV infections. Hum Vaccin 5: 671-689.
2. Chen L, Ashe S, Singhal MC, Galloway DA, Hellstrom I, Hellstrom KE (1993) Metastatic conversion of cells by expression of human papilloma virus type 16 E6 and E7 genes. Proc Natl Acad Sci USA 90: 6523-6527.
3. Galan JE, Curtiss R 3rd (1989) Cloning and molecular characterization of genes whose products allow Salmonella typhimurium to penetrate tissue culture cells. Proc Natl Acad Sci USA 86: 6383-6387.
4. Jia LJ, Xu HM, Ma DY, Hu QG, Huang XF, Jiang WH, Li SF, Jia KZ, Huang QL, Hua ZC (2005) Enhanced therapeutic effect by combination of tumor-targeting Salmonella and endostatin in murine melanoma model. Cancer Biol Ther 4: 840-845.
5. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3: 999-1005.
6. Lin KY, Lu D, Hung CF, Peng S, Huang L, Jie C, Murillo F, Rowley J, Tsai YC, He L, Kim DJ, Jaffee E, Pardoll D, Wu TC (2007) Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res 67: 1832-1841.
7. Low KB, Ittensohn M, Le T, Platt J, Sodi S, Amoss M, Ash O, Carmichael E, Chakraborty A, Fischer J, Lin SL, Luo X, Miller SI, Zheng L, King I, Pawelek JM, Bermudes D (1999) Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol 17: 37-41.
8. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S (2003) Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 24: 335-342.
9. Monie A, Hung CF, Wu TC (2007) Preventive and therapeutic HPV vaccines. Curr Opin Investig Drugs 8: 1038-1050.
10. Munger K (2002) The role of human papilloma viruses in human cancers. Front Biosci 7: d641-d649.
11. Pawelek JM, Sodi S, Chakraborty AK, Platt JT, Miller S, Holden DW, Hensel M, Low KB (2002) Salmonella pathogenicity island-2 and anticancer activity in mice. Cancer Gene Ther 9: 813-818.
12. Pawelek JM, Low KB, Bermudes D (2003) Bacteria as tumour-targeting vectors. Lancet Oncol 4: 548-556.
13. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J (2009) Postlicensure safety surveillance for quadrivalent human papilloma virus recombinant vaccine. JAMA 302: 750-757.
14. Strugnell R, Dougan G, Chatfield S, Charles I, Fairweather N, Tite J, Li JL, Beesley J, Roberts M (1992) Characterization of a Salmonella typhimurium aro vaccine strain expressing the P. 69 antigen of Bordetella pertussis. Infect Immun 60: 3994-4002.